Therefore, both ADAMTS13 antibody (i.e., titers of the highest quartile) and antigen (i.e., titers of the lowest quartile) are reported to adversely affect TTP outcome by means of elevated mortality rates as well as raised cardiac and neurological involvement [34,35,42]. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.